Neogenomics Stock News

Neogenomics Inc. (NEO) shares closed today at 0.8% above its 52 week low of $27.84, giving the company a market cap of $3B. The stock is currently down 17.8% year-to-date, down 47.6% over the past 12 months, and up 220.9% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 19.3% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.5. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 9.5% lower than its 5-day moving average, 14.0% lower than its 20-day moving average, and 31.7% lower than its 90-day moving average. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 415.7% The company's stock price performance over the past 12 months lags the peer average by -317.9% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 457.1% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Neogenomics Inc. (NEO) shares closed 1.9% lower than its previous 52 week low, giving the company a market cap of $3B. The stock is currently down 12.6% year-to-date, down 45.6% over the past 12 months, and up 235.1% over the past five years. This week, the Dow Jones Industrial Average fell 0.2%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 8.3% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.5. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 391.5% The company's stock price performance over the past 12 months lags the peer average by -277.6% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 474.6% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Sector ETF report for PSCH

Catherine Faddis, Grace Capital founder and CEO, joins 'Closing Bell' to discuss her top healthcare stock picks.

Cowen began coverage on shares of NeoGenomics (NASDAQ:NEO) in a research note published on Thursday, Analyst Ratings Network reports. The firm issued an outperform rating and a $42.00 price objective on the medical research companys stock. Other equities research analysts have also recently issued research reports about the company. Needham & Company LLC cut their []

Moody Aldrich Partners LLC cut its position in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 17.3% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 75,478 shares of the medical research companys stock after selling 15,769 shares during the period. Moody Aldrich Partners LLCs holdings in NeoGenomics were worth $3,641,000 as of its most recent filing []

NeoGenomics has established itself with a strong market position in the expanding field of cancer diagnostics. NeoGenomics is all about growth planning to grow at twice the market rate.

(PR-inside.com) FT MYERS, FL / ACCESSWIRE / December 13, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced the appointment of David Eberhard MD, PhD as Chief Medical Officer (CMO) of its liquid biopsy focused subsidiary Inivata Limited ("Inivata"). David will report to Inivata President Clive Morris and will oversee the clinical and strategic development of Inivata''s liquid biopsy tests with a particular focus on its RaDaR assay for the detection of minimal residual disease (MRD). David is a seasoned healthcare executive, bringing over 20 years'' experience in the research ..

FT. MYERS, FL / ACCESSWIRE / December 10, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading The post NeoGenomics to Leverage Thermo Fisher Scientifics Ion Torrent Genexus System in Upcoming Phase 1 Study for Myeloid Cancers first appeared on IT Business Net .